Prestige Consumer Healthcare Inc. (PBH) Company Overview

What does Prestige Consumer Healthcare do?

Prestige Consumer Healthcare Inc. is a New York Stock Exchange-listed consumer-health company whose shares trade under PBH. It develops, markets, sells, manufactures, and distributes over-the-counter healthcare and personal-care products in the United States, Canada, Australia, and selected international markets. The business is less like a research-driven pharmaceutical company and more like a focused brand owner: it buys or builds recognizable self-care brands, supports them with advertising and retail execution, and uses a relatively lean operating platform to convert consumer demand into cash flow.

Which brands define the portfolio?

Prestige owns a broad collection of need-state brands, including Monistat and Summer’s Eve in women’s health; Fleet and Dramamine in gastrointestinal and motion-sickness care; Clear Eyes and TheraTears in eye care; DenTek in specialty oral care; Compound W in dermatology; BC and Goody’s in pain relief; Little Remedies in pediatric care; Debrox in ear care; Hydralyte and Fess in Australia; and, following transactions completed after fiscal year-end, Breathe Right and the LaCorium portfolio. The official brand portfolio shows why the company matters: it competes across many routine, repeat-purchase health needs rather than relying on one therapeutic franchise.

How does Prestige Consumer Healthcare make money?

Prestige earns revenue primarily by selling branded OTC products to mass merchants, drug chains, food retailers, club stores, dollar stores, wholesalers, e-commerce channels, and international distributors. Its economics depend on consumer sell-through, shelf placement, pricing, promotion, brand advertising, product availability, and the cost of manufacturing and logistics. Unlike a subscription company, revenue must be earned repeatedly at retail; unlike a commodity producer, the company’s gross margin rests heavily on brand recognition and consumer trust.

Which segment contributes most?

North American OTC Healthcare is the economic center of the company. In fiscal 2026 it generated $913.6 million of segment revenue, or 83.9% of the $1.0887 billion total, while International OTC Healthcare generated $175.1 million, or 16.1%. North America also produced $380.0 million of contribution margin versus $66.8 million internationally. That concentration gives Prestige scale and cash generation, but it also means U.S. retailer relationships, domestic category trends, and supply execution matter disproportionately.

Which product categories matter most?

Prestige’s category mix is diversified, but not evenly. Gastrointestinal products were the largest fiscal 2026 product group at $259.8 million, followed by women’s health at $227.8 million. Eye and ear care, dermatologicals, analgesics, oral care, and cough and cold each contributed meaningful revenue. The portfolio therefore spreads risk across different consumer conditions and seasons, yet category-specific disruptions can still be material, as the Clear Eyes supply constraint demonstrated.

What does the mix say about demand?

Many Prestige products address recurring, uncomfortable, or urgent consumer needs. That tends to make demand more resilient than discretionary beauty or general merchandise, but it does not eliminate retailer inventory swings, competition, or price sensitivity. Fiscal 2026 gastrointestinal revenue rose to $259.8 million from $255.9 million, while oral care increased to $101.1 million from $95.0 million. Eye and ear care fell sharply to $142.9 million from $183.3 million, mainly because Prestige could not fully supply Clear Eyes demand. The lesson is that category demand can remain healthy while reported sales weaken when production and service levels fail.

What do fiscal 2026 results show?

Fiscal 2026 was a year of weaker reported sales but continued cash generation. Revenue declined 4.3% to $1.0887 billion. Gross profit fell 6.1% to $595.6 million, and gross margin compressed to 54.7% from 55.8%. Operating income was $309.4 million, down from $336.8 million. Net income declined to $190.3 million from $214.6 million, and diluted EPS fell to $3.91 from $4.29. The company’s fiscal 2026 earnings release also reported fourth-quarter revenue of $281.6 million, down 5.0%, while fourth-quarter net income rose to $53.9 million from $50.1 million.

Why is the Clear Eyes disruption strategically important?

The shortage exposed a critical weakness in an asset-light brand model: a strong brand cannot generate revenue if the product is unavailable. Prestige’s response was to acquire Pillar5 Pharma in December 2025. Pillar5 is a sterile ophthalmic manufacturer and had been a Clear Eyes supplier. The transaction was not financially large in fiscal 2026—Pillar5 represented roughly 2.0% of assets and 0.2% of revenue—but it was strategically important because it brought capacity, quality control, and supply-chain capability closer to the company.

How strong are margins, cash flow, and the balance sheet?

Prestige’s brand economics remain attractive. Fiscal 2026 gross margin was 54.7%, contribution margin was 41.0%, and operating margin was approximately 28.4%, calculated as $309.4 million of operating income divided by $1.0887 billion of revenue. Operating cash flow increased to $257.6 million from $251.5 million even as net income declined, helped by working-capital timing. Capital expenditures were only $11.2 million, implying approximately $246.4 million of simple free cash flow before acquisition spending.

What changed after fiscal year-end?

The balance-sheet story changed materially in June and July 2026. Prestige completed the $1.045 billion acquisition of Breathe Right, financed with cash and a new Term Loan B. It then completed the $150 million acquisition of LaCorium Health and priced $400 million of 6.25% senior notes due 2034 to refinance $400 million of 5.125% notes due 2028. The Breathe Right closing announcement describes the brand as the category leader and Prestige’s largest brand, while the LaCorium and refinancing update shows the company moving simultaneously toward more international growth and a higher interest burden.

What strategic turning points shaped Prestige?

Prestige’s current model is the result of repeated portfolio choices rather than one breakthrough invention. The company has steadily concentrated on consumer healthcare, acquired brands with established awareness, expanded internationally, and used cash flow to fund debt reduction, repurchases, and further deals.

1. 2004
   Prestige Brands was formed around a portfolio of established consumer brands, establishing the acquisition-and-brand-management model.
2. 2010s
   A series of OTC acquisitions expanded the company into women’s health, gastrointestinal care, oral care, dermatology, and pediatrics.
3. 2017
   The acquisition of C.B. Fleet strengthened gastrointestinal and women’s health and increased the scale of the portfolio.
4. 2021
   Prestige acquired TheraTears, adding a premium eye-care platform and increasing exposure to a category where manufacturing reliability later became critical.
5. 2025
   Additional Hydralyte rights expanded international ownership and reinforced Australia as a strategic market.
6. 2025
   Pillar5 brought sterile ophthalmic manufacturing capability in-house after Clear Eyes supply constraints.
7. 2026
   Breathe Right and LaCorium materially increased scale, category breadth, international exposure, and leverage.

What did these choices change?

The acquisitions widened the moat through brand breadth and retailer relevance, but they also increased integration complexity and intangible-asset concentration. At March 31, 2026, goodwill and net intangible assets totaled about $2.88 billion across the two reportable segments. That figure predates Breathe Right and LaCorium, so future balance sheets will carry even more acquisition-related assets. For analysis, this means cash returns and impairment risk matter more than book equity alone.

What gives Prestige a competitive advantage?

Prestige’s advantage is a portfolio system rather than a single patent. It combines recognizable brands, retailer relationships, category expertise, advertising scale, and a relatively efficient corporate platform. Many of its products occupy narrow consumer need states where trust, familiarity, and shelf visibility influence purchase decisions. A shopper choosing a motion-sickness remedy, wart treatment, eye drop, or women’s-health product often prefers a known brand over an unfamiliar alternative, especially when the purchase is urgent.

Who are the main competitors?

Prestige competes with diversified consumer-health groups, large pharmaceutical companies with OTC portfolios, focused category specialists, and retailer private labels. Relevant rivals vary by category and include Kenvue, Haleon, Bayer Consumer Health, Church & Dwight, Reckitt, Perrigo, and numerous smaller brands. Prestige is generally smaller than the largest global competitors, but its narrower focus can make it more attentive to mature brands that would be non-core inside a larger company. The strategic trade-off is clear: focus supports execution, while smaller scale can reduce purchasing power and increase dependence on individual suppliers and retailers.

Who owns PBH stock, and how is the company governed?

Prestige has a conventional one-class public-company structure rather than founder control or a dual-class voting system. The investor base is heavily institutional. According to the 2026 proxy statement, BlackRock beneficially owned 15.9% of outstanding shares, Ariel Investments 8.7%, Dimensional Fund Advisors 6.1%, Vanguard Portfolio Management 6.0%, and Vanguard Capital Management 5.2% as of the cited filing dates. Directors and executive officers as a group owned 716,874 shares, or 1.5%, based on 47,372,166 shares outstanding on June 10, 2026.

What does board structure signal?

Ronald M. Lombardi serves as chair and chief executive officer, while John E. Byom serves as lead independent director. All members of the Audit and Finance, Compensation and Talent Management, and Nominating and Corporate Governance committees are independent. This structure gives management strong strategic continuity but places greater importance on the lead independent director and committee oversight, particularly after large acquisitions and new financing. Executive incentives also matter because management’s stated three-pillar strategy links brand investment, free cash flow, and capital-allocation flexibility.

What risks could weaken the story?

Prestige’s principal risks are operational and financial rather than scientific. The company must keep products available, maintain retailer support, protect brand relevance, manage third-party manufacturers, comply with product regulation, and integrate acquisitions without overpaying or disrupting the base business.

Which risk is most immediate?

The most immediate issue is execution across a newly enlarged and more leveraged portfolio. Prestige must restore eye-care supply, integrate Pillar5, absorb Breathe Right, integrate LaCorium, refinance debt, and continue supporting legacy brands. Each task is manageable in isolation, but together they raise organizational complexity. The company’s low capital-expenditure model provides cash-flow capacity, yet higher interest expense and acquisition integration can consume that flexibility quickly if revenue growth disappoints.

Which KPIs and valuation drivers matter most?

A useful PBH model should focus less on headline revenue alone and more on the quality and conversion of that revenue. The company’s value depends on organic consumption, pricing, gross margin, advertising efficiency, free cash flow, debt reduction, and the return earned on acquired brands.

How should a DCF treat Prestige?

A discounted cash-flow analysis should separate the mature base portfolio from acquisition-driven growth. Revenue assumptions should reflect category growth, pricing, supply normalization, and Breathe Right and LaCorium contributions. Margin assumptions should capture advertising investment, manufacturing costs, integration synergies, and product mix. Reinvestment is unusual: routine capex is low, but acquisitions are a major form of reinvestment. Therefore, normalized free cash flow cannot be evaluated without considering periodic deal spending and debt service. The terminal case should also reflect brand durability, retailer power, private-label competition, and impairment risk rather than assuming perpetual pharmaceutical-like exclusivity.

What is the key takeaway from Prestige Consumer Healthcare analysis?

Prestige Consumer Healthcare is a focused OTC brand consolidator with attractive gross margins, low routine capital intensity, and a portfolio spread across many everyday health needs. The company’s strongest qualities are recognizable brands, retailer reach, category breadth, and strong cash conversion. Fiscal 2026 demonstrated that the model can still generate more than $250 million of operating cash flow during a year of falling revenue.

For students and researchers, Prestige is a useful case study in brand-based competitive advantage, acquisition-led strategy, and the difference between low physical capex and high economic reinvestment. For investors, the central question is not whether the brands are familiar; it is whether management can convert that familiarity into organic growth and cash returns while integrating a much larger portfolio and carrying more debt. The next phase will test whether Prestige’s three-pillar strategy—brand investment, strong free cash flow, and capital-allocation flexibility—remains self-reinforcing after its largest acquisition cycle.